Scholarlink

<p>For FluMist®/Fluenz live attenuated influenza vaccine (LAIV), efficient virus replication in human nasal epithelial cells (hNEC) is an important factor in vaccine effectiveness (VE). The necessity of antigenic similarity of LAIV viruses to the WHO-recommended strains for VE is less clear. Here, we aimed to describe the relative importance of optimal hNEC replication and antigenic match in protection from wild-type (wt) challenge in vivo. The efficacy of an A/H1N1pdm09 LAIV strain (LAIV<sub><i>H1.opt</i></sub>) with optimised hNEC replication but reduced antigenicity relative to its parent (LAIV<sub><i>H1.par</i></sub>) was assessed. Delivered at a low dose, animals vaccinated with antigenically matched LAIV<sub><i>H1.par</i></sub> shed wt challenge virus and exhibited influenza-like illness post-challenge. Conversely, antigenically divergent LAIV<sub><i>H1.opt</i></sub> provided protection from both endpoints. LAIV<sub><i>H1.opt</i></sub> was also found to be more immunogenic in ferrets than LAIV<sub><i>H1.par</i></sub>, generating superior anti-HA and anti-NA antibody responses. We conclude that efficient virus replication can supersede antigenic match for high LAIV efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Replication in human cells supersedes serum antigenic match for the in vivo efficacy of an A/H1N1pdm09 LAIV virus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Steffan Llewellyn,
  • Katarzyna E. Schewe,
  • Sameer Ayaz,
  • David Burbidge,
  • Shaun Cooper,
  • Jonathan Crowe,
  • Sarah Dodd,
  • Jemma Shapanis,
  • Katie Tudor,
  • Kathryn Ryan,
  • Lauren Parker,
  • Oliver Dibben

摘要

For FluMist®/Fluenz live attenuated influenza vaccine (LAIV), efficient virus replication in human nasal epithelial cells (hNEC) is an important factor in vaccine effectiveness (VE). The necessity of antigenic similarity of LAIV viruses to the WHO-recommended strains for VE is less clear. Here, we aimed to describe the relative importance of optimal hNEC replication and antigenic match in protection from wild-type (wt) challenge in vivo. The efficacy of an A/H1N1pdm09 LAIV strain (LAIVH1.opt) with optimised hNEC replication but reduced antigenicity relative to its parent (LAIVH1.par) was assessed. Delivered at a low dose, animals vaccinated with antigenically matched LAIVH1.par shed wt challenge virus and exhibited influenza-like illness post-challenge. Conversely, antigenically divergent LAIVH1.opt provided protection from both endpoints. LAIVH1.opt was also found to be more immunogenic in ferrets than LAIVH1.par, generating superior anti-HA and anti-NA antibody responses. We conclude that efficient virus replication can supersede antigenic match for high LAIV efficacy.